Yumanity raises $45M Series A for yeast-based drug discovery platform
Cambridge startup Yumanity Therapeutics just closed out an impressive $45 million Series A – meant to fuel its yeast-based drug discovery platform through preclinical development. The investor syndicate is an interesting blend of strategics and institutional firms. The round was led by Fidelity, with participation from Redmile Group, Alexandria Venture Investments, Biogen, Sanofi-Genzyme BioVentures and […]